Core Insights - Inhibikase Therapeutics is expanding its therapeutic pipeline with multiple late-stage development assets aimed at treating Parkinson's disease and related disorders [1][2] - The company anticipates completing the 201 Trial for untreated Parkinson's disease by the end of Q3 2024, with 94% enrollment achieved [2][5] - Inhibikase is seeking grant funding for the 202 Trial in Multiple System Atrophy through the National Institute of Neurological Diseases and Stroke [2][5] - The company is redirecting efforts for IkT-001Pro into cardiopulmonary disease, specifically targeting Pulmonary Arterial Hypertension, following a pre-IND meeting with the FDA [2][5] Company Overview - Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing therapeutics for Parkinson's disease and related disorders [4] - The company's lead program, Risvodetinib, is an Abelson Tyrosine Kinase inhibitor targeting Parkinson's disease and other related conditions [4] - Inhibikase's pipeline includes treatments for neurodegeneration, orphan indications like Multiple System Atrophy, and drug delivery technologies [4] Upcoming Milestones - Completion of the 201 Trial in untreated Parkinson's disease is expected by the end of Q3 2024, with biomarker and outcome data to be reported by the end of 2024 [5] - The company plans to submit an IND application for IkT-001Pro for Pulmonary Arterial Hypertension in early Q3 2024 [5] - Inhibikase is scaling manufacturing processes for IkT-001Pro to support late-stage clinical development and NDA batch requirements [5] - The company will discontinue development of antiviral treatments for Progressive Multifocal Leukoencephalopathy to focus on late-stage clinical assets [5]

BOSTON and ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 1,672,452 shares of common stock (or pre-funded ...

The shares of common stock (or pre-funded warrants in lieu thereof) are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-262551), which was declared effective by the U.S. Securities and Exchange Commission (the "SEC") on February 11, 2022. The warrants to be issued in the concurrent private placement and the shares issuable upon exercise of such warrants were offered pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended (the " ...

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q1 2024 Earnings Conference Call May 16, 2024 8:00 AM ET Company Participants Alexander Lobo - Stern Investor Relations Milton Werner - CEO Garth Lees-Rolfe - CFO Conference Call Participants Ed White - H.C. Wainwright Operator Greetings and welcome to Inhibikase Therapeutics First Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. [Operat ...

"2024 is shaping up to be a year of clinical and regulatory execution as we advance our core programs towards important inflection points," said Dr. Milton H. Werner, President and Chief Executive Officer of Inhibikase. "The Phase 2 201 trial for Risvodetinib ("risvo") in untreated Parkinson's disease is 83% enrolled as of May 10, 2024 and we anticipate enrolling the final patient in June with biomarker and functional assessment results to be reported in the second half of the year. On the regulatory front, ...

BOSTON and ATLANTA, May 15, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today reported financial results for the first quarter ended March 31, 2024 and highlighted recent developments. "2024 is shaping up to be a year of clinical and regul ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 26-3407249 ( State or other jurisdiction of incorporation or or ...

BOSTON and ATLANTA, May 15, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it has filed a Request for Withdrawal with the U.S. Securities and Exchange Commission ("SEC") with respect to the withdrawal of the Company's Registr ...

- FDA indicated IkT-001Pro can be considered a New Molecular Entity and is eligible for exclusivity designations in Pulmonary Arterial Hypertension – BOSTON and ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that ...

BOSTON and ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today issued a Letter to Shareholders. Dear Fellow Shareholders of Inhibikase Therapeutics: 2024 has been off to a productive start for Inhibikase. Our 201 Trial is a ...